Novartis’ radioligand therapy Lu-PSMA-617 has met its target in prostate cancer, as its $2.1 billion acquisition of specialist pharma Endocyte looks to have been justified. The big Swiss ...

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much broader prostate cancer population. The new approval, which triples ...

Novartis (NVS) announced that the Food and ... who have been treated with an androgen receptor pathway inhibitor therapy and are considered appropriate to delay chemotherapy.

Radioligand Market - Competitive Landscape The top market players in the radioligand therapy market include Novartis International AG, POINT Biopharma Global Inc., Fusion Pharma, Orano Med, Clovis ...